DanioLabs has pioneered development of medium/high throughput, high content in vivo assays utilizing its cutting edge zebrafish technology. Known drugs and pharmacological probes are screened with a view to minimizing the risk of drug development. It has two programmes with positive clinical data and a strong preclinical pipeline.
DanioLabs has a major neurodegeneration programme covering Parkinson’s, Alzheimer’s and Huntington’s diseases, as well as multiple sclerosis.
Senexis is developing new chemical entities as inhibitors of amyloid-related toxicity and inflammation in Alzheimer’s disease.
Both companies expect that the combination of the two approaches will offer an opportunity to develop molecules with potential of becoming disease-modifying therapies for Alzheimer’s disease.
Paul Goldsmith, CSO of DanioLabs said: “We are excited about this collaboration because it brings Senexis’ chemistry together with our biology. It marks an important transition for us as we move from assay development and validation to the process of identifying and progressing therapeutic candidate drugs”.
"We are delighted to be collaborating with DanioLabs," commented Dr Mark Treherne, Senexis’ Chief Executive. “We look forward to a productive and fruitful collaboration”.